Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Physiomics ( (GB:PYC) ) has shared an update.
Institutional Shareholder Services has advised investors in Physiomics to vote against resolutions at a 29 April requisitioned general meeting that seek to remove the existing board and install new directors, citing the lack of a detailed or credible business and transition plan from the requisitioning shareholders. The Physiomics board, which has also urged investors to oppose the proposals, argues that a board overhaul would be destabilising at a time when the company reports record first-half income, expects its highest-ever annual revenue and claims strong contracted visibility into the next financial year.
Spark’s Take on PYC Stock
According to Spark, TipRanks’ AI Analyst, PYC is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and persistent cash burn), partially offset by a low-leverage balance sheet and some improvement in price trend. Valuation is constrained by negative earnings and lack of dividend support.
To see Spark’s full report on PYC stock, click here.
More about Physiomics
Physiomics plc is a UK-based mathematical modelling, data science and biostatistics specialist focused on supporting biotech and pharmaceutical companies in developing new therapeutics and personalised medicine solutions. Leveraging proprietary computational tools, including its Virtual Tumour technology, the company has contributed to more than 140 commercial drug development projects for clients such as Merck KGaA, Astellas and Cancer Research UK.
Average Trading Volume: 8,383,584
Technical Sentiment Signal: Sell
Current Market Cap: £2.27M
Learn more about PYC stock on TipRanks’ Stock Analysis page.